C4 Therapeutics (CCCC) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed Zura Bio (ZURA) over the past year, gaining 31.1% versus a loss of 11.3%. C4 Therapeutics is the larger company by market cap ($388.8 million vs $383.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | ZURA |
|---|---|---|
| Share price | $3.16 | $4.00 |
| Market cap | $388.76M | $383.32M |
| 1-day change | +10.88% | -3.15% |
| YTD return | +65.45% | -23.66% |
| 1-year return | +31.12% | -11.31% |
| 5-year return | -92.80% | — |
| EPS (TTM) | $-1.01 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $7.44 |
| 52-week low | $1.69 | $3.15 |
| Distance from 52-week high | -38.88% | -46.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +321.84% | +350.00% |
| Average volume | 2.38M | 1.44M |
| Shares outstanding | 123.03M | 95.83M |
| Employees | 104 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed ZURA by 42.4 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
CCCC vs ZURA FAQ
Which is bigger, C4 Therapeutics or Zura Bio?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $388.76M compared with $383.32M for Zura Bio (ZURA).
Which stock has performed better over the past year, CCCC or ZURA?
CCCC returned +31.12% over the past 12 months, compared with -11.31% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.